PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Quotes for PharmaLundensis AB

Right Now

+/-
-0.01
%
-1,17%
Latest
0.844
High
0.844
Low
0.802
Volume
13 163
Turnover (SEK)
10 577
Market Value (MSEK)
25,1
Time (Latest trade)

Board

CEO

  • Staffan Skogvall

Chairperson of the Board

  • Arne Skogvall

Board

  • Bo Wennergren
  • Björn Sivik
  • Staffan Skogvall
  • Stefan Ahlfors

Largest Owners

Name Capital % Votes % Date
Arne Skogvall 35,54 35,54 2022-06-28
Staffan Skogvall 9,80 9,80 2022-06-28
Avanza Pension 1,85 1,85 2022-06-28
Vict Th Engwalls Stiftelse 1,75 1,75 2022-06-28
Henrik Skog 1,66 1,66 2022-06-28
Arian Ismail 1,52 1,52 2022-06-28
Nordnet Pensionsförsäkring 1,13 1,13 2022-06-28
Staffan Engelbert Bodén 0,83 0,83 2022-06-28
Torsten Ingemar Jonsson 0,72 0,72 2022-06-28
Tommy Johansson 0,60 0,60 2022-06-28
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2022-08-18 Delårsrapport 2022-Q2

  • 2022-11-17 Delårsrapport 2022-Q3

  • 2023-02-16 Bokslutskommuniké 2022

Annual reports, prospectus etc.